November 13, 2018 Clinical Research/Diagn. Product Launch

New Diagnostic Test Helps Hospitals More Quickly Identify and Treat Emerging Antibiotic-Resistant Bacteria

Fully-automated BD Phoenix™ CPO Detect Test Receives U.S. FDA Clearance FRANKLIN LAKES, N.J., Nov. 13, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of the BD Phoenix™ CPO detect test, which will allow hospitals to identify infections caused by carbapenemase-producing organisms (CPOs). The... Read more

November 13, 2018 Clinical Research/Diagn. Product Launch

New Diagnostic Test Helps Hospitals More Quickly Identify and Treat Emerging Antibiotic-Resistant Bacteria

FRANKLIN LAKES, N.J., Nov. 13, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of the BD Phoenix™ CPO detect test, which will allow hospitals to identify infections caused by carbapenemase-producing organisms (CPOs). The test may help hospitals contain the... Read more

November 7, 2018 Clinical Research/Diagn.

BD Announces Clinical Trial Data for the LUTONIX® 014 Drug-Coated Balloon Below-The-Knee IDE Trial

FRANKLIN LAKES, N.J., Nov. 7, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the safety and efficacy data from the LUTONIX® Drug-Coated Balloon (DCB) IDE, level 1 clinical trial for a below-the-knee (BTK) indication. The clinical study is a prospective, global, multicenter, randomized, controlled trial comparing... Read more

November 6, 2018 PR/Corporate

BD to Present at the Stifel 2018 Healthcare Conference

FRANKLIN LAKES, N.J., Nov. 6, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018, at 11:45 AM ET. A live webcast of BD’s presentation can be accessed from the BD corporate website at... Read more

October 23, 2018 Clinical Research/Diagn.

BD To Invest $200 Million In Nebraska Operations Creating 300 More Jobs

Brings Total Company Investment in Nebraska to $340 Million in Two Years COLUMBUS, Neb., Oct. 23, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined today by Gov. Pete Ricketts and other state and local leaders to announce a $200 million investment in its facilities in Nebraska that will create 300 new jobs statewide. Today’s... Read more

October 23, 2018 Uncategorized

BD To Invest $200 Million In Nebraska Operations Creating 300 More Jobs

COLUMBUS, Neb., Oct. 23, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined today by Gov. Pete Ricketts and other state and local leaders to announce a $200 million investment in its facilities in Nebraska that will create 300 new jobs statewide. Today’s announcement brings BD’s commitment... Read more

October 17, 2018 PR/Corporate

BD Donates 20 Million Syringes to Support Polio Eradication

Company Joins Effort Alongside Rotary and Leading Global Health Organizations to Expand Vaccinations in India FRANKLIN LAKES, N.J., Oct. 17, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a donation of 20 million syringes valued at $1 million to Rotary, a nonprofit organization dedicated to tackling the world’s most... Read more

October 16, 2018 Clinical Research/Diagn. Licensing, IP, and Legal Life Science Tools Product Launch

BD Launches Molecular Test For Detecting Tuberculosis And Multi-Drug Resistant TB

BD MAX™ MDR-TB Panel Obtains CE-IVD Status in Europe FRANKLIN LAKES, N.J., Oct. 16, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the availability of the BD MAX™ MDR-TB panel in Europe. Clinicians can use the test to simultaneously detect bacteria that cause tuberculosis (TB) and determine if the bacteria... Read more

October 3, 2018 Uncategorized

BD Breaks Ground at I.D.E.A. Tempe Campus

Global Medical Technology Company To Be Anchor Tenant at New Campus TEMPE, Ariz., Oct. 3, 2018 /PRNewswire/ — Officials from BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, were joined today by Gov. Doug Ducey, Tempe Mayor Mark Mitchell and representatives of The Boyer Company to officially break ground on the new I.D.E.A. (Innovation, Discovery, Education and Arts)... Read more

October 3, 2018 PR/Corporate

Tom Polen Promoted to Chief Operating Officer of BD

FRANKLIN LAKES, N.J., Oct. 3, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Tom Polen will add the responsibility of chief operating officer of BD, in addition to his current role as president. Polen continues to report Vincent A. Forlenza, chairman and CEO. As president and chief operating officer, Polen... Read more